France Plans to Expand Medical Cannabis Program by Mid-2024
France plans to expand its medical cannabis program nationwide by mid-2024, integrating it into the 2024 Social Security Financing Bill
Key Points
- 1France to expand medical cannabis program by mid-2024
- 2Integration into 2024 Social Security Financing Bill planned
- 3Regulatory framework for cultivation to be finalized
- 4Supply shortages addressed through new tenders
- 5Plans for domestic production line in development
The French health authorities have announced plans to expand the medical cannabis program across the nation by mid-2024. This decision, revealed during a recent meeting organized by the Direction Générale de la Santé (DGS), marks a significant step forward following the initial experimental phase. The meeting outlined scenarios for transitioning from the experimental phase to a more permanent framework, with plans to integrate this transition into the 2024 Social Security Financing Bill
The experimental phase, which initially faced challenges due to supply shortages, is now set to conclude with a structured exit strategy. The DGS has been working on finalizing regulations related to the cultivation of medical cannabis, which will be notified at the European level. This regulatory framework aims to ensure a seamless transition and address previous supply chain issues that affected patients relying on medical cannabis products
Key stakeholders have expressed optimism about the government's commitment to expanding the medical cannabis program. The authorities are considering various regulatory options for cannabis-based medical products, including whether to require marketing authorization (AMM) or to create an intermediate status. This flexibility is intended to avoid overly restrictive access to these products, which are crucial for many patients
Despite the positive outlook, the program has faced criticism for its handling of supply shortages during the experimental phase. The initial supplier, responsible for 60% of the products, did not participate in new tenders due to financial constraints, resulting in stock shortages. The DGS has since launched a second tender to address these issues and ensure continuous supply for patients
Looking ahead, the DGS plans further discussions to establish a domestic production line for medical cannabis, which could bolster the program's sustainability. These efforts are part of a broader strategy to create a robust medical cannabis industry in France, which could potentially position the country as a leader in the European cannabis market